Magazine Article | June 7, 2017

Bridging The Gap Between Academia, Small Biotechs, And Industry

By Suzanne Elvidge, Contributing Editor
Follow Me On Twitter @suzannewriter

Academia and biotech have long been sources of innovation for the pharmaceutical industry, and this is increasingly important for Big Pharmas that want to prop up flagging pipelines or boost particular areas of focus. Some of the large pharma companies have started to reach out to academia through formal programs, such as GSK’s Discovery Partnerships with Academia (DPAc), or Merck’s support of the California Institute for Biomedical Research (Calibr). However, academia, research institutions, and small biotechs can find it challenging to reach back the other way and get their voices heard by pharma companies and bigger biotechs.

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.